by GOT | Sep 1, 2021 | Legacy Arbor Archives
Arbor Supports Updated Clinical Recommendations for Restless Legs Syndrome Arbor has long recognized the need for effective treatment options for Restless Legs Syndrome (RLS) and support for the patients who suffer from it. We are pleased to support The Updated...
by GOT | Aug 24, 2021 | News
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc....
by GOT | Feb 8, 2021 | News
Azurity Pharmaceuticals Announces Three New Neurology Products WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care,...
by GOT | Aug 27, 2020 | Legacy Arbor Archives
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty Company orders additional product amid reported industry shortage ATLANTA, Aug. 25, 2020 – Arbor Pharmaceuticals, LLC, a U.S.-based specialty...
by GOT | Jul 10, 2019 | News
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for...
Recent Comments